Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD
- High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally
- Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody targeting TSLP ligand as well as building a discovery pipeline of long-acting bispecifics
- Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, to join the Windward Bio Board of Directors
COPENHAGEN, Denmark. Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio. Headquartered in Switzerland, Windward Bio is a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions.
